Abstract
This issue of Blood presents a tour de force: Trotman and colleagues1 report a phase 1/2 trial of zanubrutinib, a novel Bruton tyrosine kinase (BTK) inhibitor, and lay the groundwork for Tam et al.2 to present a head-to-head comparison of 2 BTK inhibitors, zanubrutinib and ibrutinib, in MYD88L256P mutantWaldenström macroglobulinemia (WM). These companion articles on zanubrutinibwill arguably have broad implications in WM therapeutics. The 2 trials showcase how extraordinary international collaborative efforts were instrumental in the development of zanubrutinib at warp speed for treatment of a rare B-cell malignancy.
Original language | English (US) |
---|---|
Pages (from-to) | 1997-1999 |
Number of pages | 3 |
Journal | Blood |
Volume | 136 |
Issue number | 18 |
DOIs | |
State | Published - Oct 29 2020 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology